The earnings call reflected strong growth in revenue, international expansion, and positive developments in product pipelines and cash flow management. However, the gross margin decline and anticipated challenges with U.S. distributor inventory reductions present areas of concern. Overall, the positive aspects significantly outweigh the negatives.

Company Guidance

During the KORU Medical Systems second quarter 2025 financial results conference call, the company reported a historic milestone with over $10 million in revenue, reflecting a 21% growth year-over-year. The domestic core revenues reached $7.1 million, marking a 15% increase, while international core business revenues grew by 34% to $2.2 million. The Pharma Services and Clinical Trials segment saw a 42% revenue growth, totaling $900,000. Gross margins declined by 150 basis points to 63.5%, affected by tariff impacts and prior year inventory adjustments. However, the company maintained a strong cash balance of $8.1 million, with a cash usage of $600,000 for the quarter. KORU raised its revenue guidance for 2025 to $39.5 to $40.5 million, indicating an 18% to 20% growth and anticipates achieving positive cash flow from operations for the full year. The guidance reflects confidence in international market expansion and pharmaceutical services growth, despite anticipated domestic distributor inventory reductions in Q3.

Record Revenue Milestone

KORU Medical Systems achieved over $10 million in revenue for Q2 2025, marking more than a 20% year-over-year growth.

Significant International Expansion

International revenues grew by 34%, driven by expansion into new geographies and success with the prefilled syringe strategy in Europe.

Pharma Services and Clinical Trials Growth

The Pharma Services and Clinical Trials segment saw a 42% growth, driven by clinical trial orders from a non-Ig partner.

FDA Approvals and Submissions

FDA approved an expanded indication for Empaveli, and a 510(k) submission was made ahead of schedule for a rare disease biologic.

Positive Cash Flow Trajectory

Q2 cash usage was reduced to $600,000, with expectations for neutral to positive cash flow in the second half of 2025.

Next-Generation Product Developments

Launched Phase I flow controller ahead of schedule and on track with next-gen pump development, with a 510(k) submission expected by Q4 2025 to Q1 2026.

REPRO-MED Systems (KRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KRMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.02 / -	-0.03	―	―	―
Aug 06, 2025	2025 (Q2)	-0.02 / 0.01	-0.01	200.00% (+0.02)
May 07, 2025	2025 (Q1)	-0.03 / 0.00	-0.04	―
Mar 12, 2025	2024 (Q4)	-0.03 / -0.03	-0.02	-50.00% (>-0.01)
Nov 13, 2024	2024 (Q3)	-0.04 / -0.03	-0.03	0.00% (0.00)
Aug 07, 2024	2024 (Q2)	-0.04 / -0.01	-0.05	80.00% (+0.04)
May 01, 2024	2024 (Q1)	-0.04 / -0.04	-0.05	20.00% (+0.01)
Mar 13, 2024	2023 (Q4)	-0.04 / -0.02	-0.04	50.00% (+0.02)
Nov 08, 2023	2023 (Q3)	-0.05 / -0.03	-0.03	0.00% (0.00)
Aug 09, 2023	2023 (Q2)	-0.06 / -0.05	-0.06	16.67% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KRMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$3.26	$3.87	+18.71%
May 07, 2025	$2.72	$3.29	+20.96%
Mar 12, 2025	$3.28	$2.70	-17.68%
Nov 13, 2024	$3.20	$3.08	-3.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does REPRO-MED Systems (KRMD) report earnings?

REPRO-MED Systems (KRMD) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is REPRO-MED Systems (KRMD) earnings time?

REPRO-MED Systems (KRMD) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KRMD EPS forecast?

KRMD EPS forecast for the fiscal quarter 2025 (Q3) is -0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing